But I'll say that coming to Nashville for Daxify, the live part was not a rate limiter for us choosing the appropriate folks. that we want to put into our Preview program. Yeah, and I think part of the reason we were able to move up the Preview program to early December versus early in Q1 is that in reaching out to a lot of these accounts, we found that there was strong interest in actually participating in an in-person session. So we'll have a lot more flexibility as we move through Preview to offer virtual sessions and in practice, but we've been very pleased with the receptivity of this group to want to travel to Nashville for the Preview program.

Nov 8, 2022 / receipt, needs a key / Mark, CEO | earnings call 2022-11-08 | transcript 4b434952-f379-4b50-9381-7a70d40c7000 | chars 32519-33177 | segment 32

As of today, the FDA has not scheduled or conducted the pre-approval inspection of our Northern California manufacturing facility due to COVID-19 related travel restrictions.

May 10, 2021 / receipt, needs a key / Mark Foley, CEO | earnings call 2021-05-10 | transcript 1bb3c6f4-c807-4f63-8521-0bcceb48cd53 | chars 3699-3873 | segment 3

As a reminder, the approval of our BLA by the PDUFA date of November 25, 2020, was deferred due to FDA's inability to conduct an inspection of our facility due to COVID-related travel restrictions.

May 10, 2021 / receipt, needs a key / Mark Foley, CEO | earnings call 2021-05-10 | transcript 1bb3c6f4-c807-4f63-8521-0bcceb48cd53 | chars 4580-4777 | segment 4

However, as we announced in November, the BLA for Glabella Lines remains in review due to the FDA's inability to conduct a mandatory inspection of our manufacturing facility as a result of COVID-19 travel restrictions.

Feb 22, 2021 / receipt, needs a key / Mark, CEO | earnings call 2021-02-22 | transcript 5cfc2b3d-d5b1-4d79-aac0-19a9db12363f | chars 13240-13458 | segment 13